Novartis AG (NVS)
$143.75+0.45%Close
BUYRECOVERY · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $273.2B
- Beta
- 0.42
- Div yield
- 3.37%
- P/E (TTM)
- 21.36
- Short % float
- 0.31%
- Days to cover
- 2.9
- SI change
- +8.2%
- 1W
- +1.95%
- 1M
- +4.56%
- vs SPY 1W
- +0.79%
- vs SPY 1M
- +1.57%
Industry peers
FMP comparable companies · ranked by market cap
- JNJSELLJohnson & Johnson$618.1BBEARQ 22$256.48+1.93%
- ABBVBUYAbbVie Inc.$481.3BBULLQ 29$272.42+1.49%
- MRKSELLMerck & Co., Inc.$351.7BBEARQ 11$142.40+2.26%
- AZNSELLAstraZeneca PLC$246.2BRECOVERYQ 20$158.78+0.26%
- GILDSELLGilead Sciences, Inc.$182.4BBULLQ 25$147.10+2.77%
- NVOSELLNovo Nordisk A/S$169.5BRECOVERYQ 20$38.18+1.20%
- PFESELLPfizer Inc.$158.6BBULLQ 13$27.82+1.65%
- BMYSELLBristol-Myers Squibb Company$121.7BBEARQ 10$59.58-0.77%
- SNYSELLSanofi$96.6BBEARQ 11$40.23-0.40%
- GSKSELLGSK plc$93.2BRECOVERYQ 14$46.54-0.09%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NVS?
- LOPJLB’s latest quantitative signal on Novartis AG (NVS) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is NVS in?
- Novartis AG (NVS) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Novartis AG (NVS) do?
- Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on Fe…